Healthcare company Perrigo Company plc (NYSE:PRGO) (TASE:PRGO) disclosed on Wednesday the receipt of the tentative approval from the US Food and Drug Administration for the generic version of Prolensa (bromfenac ophthalmic solution) 0.07% for treating ocular pain in patients.
In conjunction with the US FDA's tentative approval,the company has settled litigation with Bausch & Lomb Inc for Prolensa (bromfenac ophthalmic solution) 0.07%.
According to the company, Prolensa (bromfenac ophthalmic solution) 0.07% is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery.
For the last 12 months, the branded market sales of Prolensa Ophthalmic Solution 0.07% were approximately USD113m, concluded the company.
Biocon's first US manufacturing facility inaugurated in Cranbury, New Jersey
Amneal's risperidone extended-release injectable suspension approved by US FDA
First FDA acceptance to waive clinical efficacy studies for monoclonal antibody biosimilars
Coya Therapeutics wins FDA clearance to advance COYA 302 into Phase 2 ALS trial
Viatris' generic iron sucrose injection gains US FDA approval
Newbury Pharmaceuticals gains Finnish approval for generic melatonin
CivicaScript to distribute biosimilar for chronic inflammatory conditions
Mallinckrodt and Endo complete merger
Zenara Pharma's Sertraline Hydrochloride Capsules generic receives US FDA approval
Mallinckrodt receives Irish High Court ruling to combine with Endo Inc
Accord Healthcare introduces Dehydrated Alcohol Injection for cardiovascular indications
CivicaScript introduces low-cost multiple sclerosis treatment
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Glenmark Therapeutics launches Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC)